Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1731 - FcγR IIA and IIIA polymorphisms predict clinical outcome of trastuzumab treated metastatic gastric cancer


08 Oct 2016


Poster Display


Ruihua Xu


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


R. Xu, D. Wang

Author affiliations

  • Department Of Medical Oncology, Cancer Centre Sun Yat-Sen University, 510060 - Guangzhou/CN


Abstract 1731


Trastuzumab has substantial anti-tumor activity in metastatic gastric cancer, and one mechanism is antibody-dependent cell-mediated cytotoxicity (ADCC), which has been reported to be influenced by FcɣR II A and III A polymorphisms. This retrospective study is the first to assess their impact on trastuzumab efficacy in patients with metastatic gastric cancer.


We retrospectively included 42 Her-2 positive patients receiving fluorouracil and platinum based chemotherapy and trastuzumab, and 68 Her-2 negative patients receiving fluorouracil and platinum based chemotherapy only as first line treatment. FcɣR II A and III A polymorphisms were assessed and their associations with efficacy in both settings were analyzed.


In patients treated with trastuzumab, FcɣR II A H/H genotype was associated with significantly superior progression-free survival (PFS) (hazard ratio (HR) and 95% confidence interval (CI): 0.36 (0.16-0.82), adjusted HR and 95% CI: 0.18 (0.07-0.48), P = 0.001). Combining FcɣR II A and III A polymorphisms, FcɣR II A H/H or FcɣRIII A V/V genotype was associated with significantly improved disease control rate (DCR) (P = 0.04) and PFS (HR and 95% CI: 0.29 (0.13-0.67), adjusted HR and 95% CI: 0.17 (0.07-0.45), P 


FcɣR II A and III A polymorphisms might predict DCR and PFS in metastatic gastric cancer receiving trastuzumab treatment.

Clinical trial identification

Legal entity responsible for the study



Major Special Project from Guangzhou Health and Medical Collaborative Innovation (No. 201508020247).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings